20.02.2013 - Sobi and Savient Pharmaceuticals will co-market the Swedish company's arthritis drug Kineret (anakinra) in the U.S.
The copy of the human IL-1 receptor antagonist, which is produced in E. coli bacteria, reduces the symptoms and progression of rheumatoid arthritis (RA) by binding the access of IL-1 that causes inflammation in the joints. With the agreement Swedish Orphan Biovitrum (Sobi) hopes to expand its reach to US physicians, said Sobi COO Alan Raffensperger.
Savient's specialised sales force has strong, established relationships with rheumatologists in the US. "Kineret complements the strategic direction and focus of Savient, as we continue to build upon our existing relationships with rheumatologists and patients while marketing our own product, Krystexxa“, said Lou Ferrari, President and Chief Executive Officer of Savient.
Under the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the US. Savient will market and promote Kineret beginning April 1, 2013. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities.
Kineret is approved as second line treatment for moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease modifying anti-rheumatic drugs (DMARDs).
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.